Home

JEAN JACQUES BIENAIME

CIK 1221590 · Chief Executive Officer · last filed 2026-08-19

JEAN JACQUES BIENAIME is a Chief Executive Officer who has filed 464 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing shows the insider bought $10.3K of KROS on Aug 19, 2026. Across all open-market trades the lifetime net is −$239.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $35.8M across reported positions. 399 SEC filings were submitted jointly with BIOMARIN PHARMACEUTICAL INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$35.80M

Companies

6

Total Filings

464

Lifetime Open-Market Net

-$239.83M

Filer Profile

Reported Address
925 PAGE MILL ROAD
PALO ALTO, CA 94304
Related Filers
BIOMARIN PHARMACEUTICAL INC — 399 joint filings, latest 2024-05-31
INCYTE CORP — 46 joint filings, latest 2026-06-10
INTERMUNE INC — 6 joint filings, latest 2014-10-01
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KROS Director 19,592 $11.08 $217.1K $75.8K 9 2026-08-19
ASND Director 2,000 $263.51 $527.0K $699.3K 3 2026-08-18
IMNM Director 38,915 $24.67 $960.0K $437.4K 12 2026-06-12
INCY Director 24,424 $121.47 $2.97M $320.5K 45 2026-06-10
BMRN Director 473,892 $65.68 $31.13M -$241.37M 336 2024-05-21
PORTOLA PHARMACEUTICALS INC (PTLA) Delisted Director 1,706 — — $3.9K 4 2014-03-10

Recent Filings

464 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-19 KROS Buy (P) +1,000 $10.3K EDGAR
2026-08-18 ASND Buy (P) +2,000 $492.7K EDGAR
2026-07-17 KROS Buy (P) +1,000 $10.6K EDGAR
2026-06-17 KROS Buy (P) +1,000 $10.2K EDGAR
2026-06-12 IMNM Grant (A) — $0 EDGAR
2026-06-10 INCY Grant (A) +1,642 $0 EDGAR
2026-06-09 IMNM Mixed — $440 EDGAR
2026-06-05 KROS Grant (A) +7,142 $0 EDGAR
2026-06-01 ASND Buy (P) +500 $111.6K EDGAR
2026-05-28 INCY Mixed +1,941 -$79 EDGAR
Showing 1–10 of 464
Page 1 of 47
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.